Vildagliptin more effectively achieves a composite endpoint of HbA1c<7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment

Diabetes Research and Clinical Practice

Volumn 100, Issue 3, 2013, Pages

  Bader, Giovanni ^a   Geransar, Parnia ^b   Schweizer, Anja ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Pharmaceuticals UK Ltd   (United Kingdom)

Author keywords

Composite endpoint; Dipeptidyl peptidase 4 (DPP 4) inhibitors; Incretin based therapy; Type 2 diabetes (T2D); Vildagliptin

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; VILDAGLIPTIN;

ADD ON THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ADAMANTANE; AGED; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NITRILES; PYRROLIDINES; SULFONYLUREA COMPOUNDS; WEIGHT GAIN;

EID: 84878483977     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.03.011     Document Type: Article

References (15)

1. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
2. American Diabetes Association Standards of medical care in diabetes - 2012. Diabetes Care 2012, 35(Suppl. 1):S11-S63.
3. Amiel S.A., Dixon T., Mann R., Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008, 25:245-254.
4. Hermansen K., Mortensen L.S. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007, 30:1127-1142.
5. Ahrén B., Schweizer A., Dejager S., Villhauer E.B., Dunning B.E., Foley J.E. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011, 13:775-783.
6. Keating G.M. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010, 70:2089-2112.
7. Ferrannini E., Fonseca V., Zinman B., Matthews D., Ahrén B., Byiers S., et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009, 11:157-166.
8. Matthews D.R., Dejager S., Ahren B., Fonseca V., Ferrannini E., Couturier A., et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010, 12:780-789.
9. Seck T.L., Engel S.S., Williams-Herman D.E., Sisk C.M., Golm G.T., Wang H., et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Res Clin Pract 2011, 93:e15-e17.
10. Zinman B., Schmidt W.E., Moses A., Lund N., Gough S. Achieving a clinically relevant composite endpoint outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012, 14:77-82.
11. Gallwitz B., Bohmer M., Segiet T., Mölle A., Milek K., Becker B., et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 2011, 34:604-606.
12. Bourdel-Marchasson I., Schweizer A., Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract (Minneap) 2011, 39:7-21.
13. Tayek J. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes Obes Metab 2008, 10:1128-1130.
14. Zoungas S., Chalmers J., Kengne A.P., Pillai A., Billot L., de Galan B., et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract 2010, 89:126-133.
15. Filozof C., Gautier J.-F. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010, 27:318-326.